Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Corcept Therapeutics (NQ: CORT ) 28.80 -0.08 (-0.28%) Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 547,807 Open 28.64 Bid (Size) 27.13 (1) Ask (Size) 29.50 (1) Prev. Close 28.88 Today's Range 28.44 - 29.11 52wk Range 20.87 - 34.27 Shares Outstanding 115,926,629 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. May 10, 2024 Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation. Via Chartmill 10 Health Care Stocks With Whale Alerts In Today's Session May 09, 2024 Via Benzinga Performance YTD +19.21% +19.21% 1 Month +29.15% +29.15% 3 Month +27.55% +27.55% 6 Month +13.30% +13.30% 1 Year +16.88% +16.88% More News Read More Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout. May 09, 2024 Via Chartmill The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts May 02, 2024 Via Benzinga CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 01, 2024 Via InvestorPlace Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update May 01, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Recap: Corcept Therapeutics Q4 Earnings February 15, 2024 Via Benzinga Earnings Scheduled For February 15, 2024 February 15, 2024 Via Benzinga Corcept Completes Enrollment in Phase 4 CATALYST Trial April 29, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call April 24, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter April 22, 2024 Via Benzinga Exposures Product Safety Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome April 22, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Earnings Preview: Corcept Therapeutics February 14, 2024 Via Benzinga While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. April 19, 2024 Via Chartmill Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) April 15, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer April 08, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome April 01, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. March 29, 2024 Via Chartmill Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation. March 07, 2024 Via Chartmill What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday? February 16, 2024 Via Benzinga Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update February 15, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial February 15, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. February 14, 2024 Via Chartmill Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call February 08, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Appoints Roberto Vieira as President, Oncology January 29, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
